Lipella Pharmaceuticals Inc.
LIPO
$0.593
-$0.0002-0.03%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -33.00% | -25.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -33.00% | -25.50% | |||
| Cost of Revenue | -20.32% | -6.48% | |||
| Gross Profit | 18.42% | 2.77% | |||
| SG&A Expenses | 40.54% | -17.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.95% | -10.33% | |||
| Operating Income | -2.17% | 8.51% | |||
| Income Before Tax | -1.61% | 9.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.61% | 9.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.61% | 9.38% | |||
| EBIT | -2.17% | 8.51% | |||
| EBITDA | -2.17% | 8.51% | |||
| EPS Basic | 51.46% | 46.69% | |||
| Normalized Basic EPS | 51.46% | 46.69% | |||
| EPS Diluted | 51.56% | 46.29% | |||
| Normalized Diluted EPS | 51.46% | 46.69% | |||
| Average Basic Shares Outstanding | 109.32% | 69.98% | |||
| Average Diluted Shares Outstanding | 109.32% | 69.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||